Company

About DIAGENICS

Human life, Early Diagnostics, Innovation - these are the corporate values ​​of DIAGENICS that drive us.
Diagenics Group SE

INNOVATION FOR LIFE

Diagenics Group SE is a biopharmaceutical enterprise with branch offices and partners in Europe and the USA. We are developers and producers of a new product line of diagnostic tools based on a new and innovative bio-marker. The potential of our products will change and improve the medical diagnosis.

With the help of our new products, not only are we capable of diagnosing a myocardial infarction - also known as ACS (Acute Coronary Syndrome) - quicker and more accurately, but also can we perform faster, safer and more effectively.

The health system can also benefit from it, as cost-effectiveness can be increased by getting earlier and more precise resources and by reducing the frequency of misdiagnosis.

We are making decisive changes to early diagnosis in the areas of heart attacks, strokes and serious pregnancy complications.
Innovation for life
Innovation for life
Our main focus is on the early detection of heart attacks, strokes and preeclampsia, we are also currently developing diagnostic equipment to detect COVID-19 infection. It is not difficult to imagine that the development of promising new diagnostic technology for the two largest disease fields worldwide will have an immense influence of our products on the world market.
Diagenics Group SE

Our Team

Management Team

Ernest Kapetanovic, CEO & Founder
Sam Yastas, COO & Co-Founder
Hermann Josef Ernst, Board Member

Scientific Advisory Board

Prof. Dr. Reiner Körfer
Prof. Dr. Siegfried Seeber
Prof. Dr. med. Georg V. Sabin
Prof. Dr. med. Louise Kenny
Prof. Dr. Mario Dicato
Prof. Dr. Pierre Khuri Yakub
Dr. Aaron Kugelmass

Business Advisory Board

Ted Lord
Peter Dijkmans
Karl-Peter von Habsburg
Prof. Manfred Maus
Dr. Michael Silverman

Company

Discover

DIAGENICS Group SE

Segments

DIAGENICS Group SE

Products

DIAGENICS Group SE

Research & Development

DIAGENICS Group SE

Investors